Chesapeake IRB launches CIRBI in Canada
The integration of Chesapeake IRB and IRB Services is now complete.
After joining forces in April of this year, Chesapeake IRB and IRB Services, both North American leaders in providing central ethical review services, began making plans to integrate submission processes in the United States and Canada utilizing a common, powerful, proven, electronic platform, CIRBI. The integration is now complete. Chesapeake IRB's revolutionary platform, the Center for IRB Intelligence (CIRBI), provides cloud-based access to an entire ethics review project. The fully integrated system unifies all Chesapeake IRB and IRB Services functions under one easy-to-use platform.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
